Skip to content

Weicon (Tefilicon) Hydrophilic Contact Lens

by Ciba Vision Care

PMA P810005

Active United States

PMA

Valid until

No expiry

PMA approval is not time-limited

FDA recalls

None found

in data synced 22 Oct 2026

Documents

PMA P810005↗

FDA record

Trust

Unverified

Registry data, not yet checked by deviCERTS. Source FDA PMA, synced 22 Oct 2026. What this means

Regulatory status

as of registry sync 22 Oct 2026

RegionAuthorizationNumberDateStatus
United StatesFDA PMAAPPR Approved 1 supplement NumberP810005 Date7 Jun 1988ApprovedStatusActive

Recalls

0 recalls · FDA

No FDA recalls found in the data synced 22 Oct 2026.

Coverage

1 jurisdiction

United States of America
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not covered

United States — FDA PMA Active

Specification

PMA

Full name
Weicon (R) (Tefilicon) Hydrophilic Contact Lens
Generic Name
Lenses, soft contact, daily wear
PMA Number
FDA Product Code
LPL
Device Class
Class II
Regulation
21 CFR Part 886.5925
Advisory Committee
Ophthalmic
FDA Decision
APPR Approved
PMA Supplement
S014

Overview

AI-generated summary, 18 Sep 2026

Written by a language model from registry data. Not verified by deviCERTS or the manufacturer. The registry data above is the record.

This device is a Lens, Soft Contact, Daily Wear, designed for corneal or scleral placement to correct refractive errors or improve vision. The hydrophilic material ensures compatibility with the eye’s natural tear film, providing comfort and clarity for daily use. As classified under FDA nomenclature, it is intended for short-term wear, typically removed at night.

The Weicon (Tefilicon) Hydrophilic Contact Lens is supplied as a single-use, sterile product for ophthalmic use only. It is regulated under FDA_PMA with approval number P810005 and product code LPL, adhering to 21 CFR 886.5925. Available in multiple registration numbers (e.g., 3015533540), it is intended for professional fitting by eye care practitioners in clinical or home settings. Storage instructions and MRI safety are not specified in the data.

Other devices from Ciba Vision Care

See all devices from Ciba Vision Care →

Questions

AI-generated answers, 18 Sep 2026

Written by a language model from registry data. Not verified by deviCERTS or the manufacturer. The registry data above is the record.

  • Are these contact lenses designed for overnight wear, or are they meant to be removed at night like daily-wear lenses typically are?

    The Weicon (Tefilicon) Hydrophilic Contact Lens is explicitly classified as a daily-wear device, meaning it is intended for short-term use and should be removed at night. This design aligns with its FDA_PMA approval (P810005) under product code LPL, which specifies it is not for continuous or extended wear.

  • How are these lenses supplied, and what should I know about their sterility and single-use nature?

    The Weicon (Tefilicon) Hydrophilic Contact Lens is supplied as a single-use, sterile product for ophthalmic use only. Each lens is intended for one-time wear and disposal, ensuring hygiene and reducing the risk of infection. The sterility is maintained through manufacturing controls, but no specific storage instructions (e.g., refrigeration or expiration) are provided in the data.

  • Are there multiple sizes or models available for this contact lens, and how would I determine the correct fit?

    While the data lists numerous registration numbers (e.g., 3015533540), these are administrative identifiers and do not directly indicate specific sizes or models. The lens is designed for corneal or scleral placement to correct refractive errors, so the correct fit would be determined by an eye care practitioner during a professional fitting, as required by the device’s intended use.

  • What regulatory pathway was followed for this device’s approval, and what does that mean for clinicians or buyers?

    The Weicon (Tefilicon) Hydrophilic Contact Lens was approved through the FDA’s Premarket Approval (PMA) process, indicated by the PMA number P810005 and product code LPL. This pathway ensures rigorous evaluation of safety and effectiveness for Class II devices, meaning clinicians and buyers can rely on established standards for performance and compliance with 21 CFR 886.5925. The approval does not imply overnight wear but confirms suitability for daily use.